Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers
Top Cited Papers
- 1 December 2016
- journal article
- review article
- Published by Elsevier BV in Lung Cancer
- Vol. 102, 122-134
- https://doi.org/10.1016/j.lungcan.2016.10.010
Abstract
No abstract availableKeywords
This publication has 173 references indexed in Scilit:
- Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung CancerPLOS ONE, 2013
- EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted TherapyPLOS ONE, 2013
- EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinomaCellular Oncology, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Mitochondrial DNA mutations in respiratory complex‐I in never‐smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutationJournal of Cellular Physiology, 2011
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancerBritish Journal of Cancer, 2007
- Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinibBritish Journal of Cancer, 2007
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986